Cochlear (ASX: COH) — Perfil da empresa, notícias e dados financeiros
Cochlear Limited develops and manufactures implantable hearing solutions, improving the lives of individuals with hearing loss.
Cochlear
Cochlear is a global medical device company that designs, manufactures, and distributes implantable hearing solutions for children and adults affected by moderate to profound hearing loss. The company produces fully implantable and semi-implantable cochlear systems, bone conduction hearing devices, and acoustic implants designed to bypass damaged portions of the outer or middle ear. Headquartered in Sydney, Australia, the organization maintains primary research, development, and manufacturing operations across Australia, Sweden, Belgium, and Malaysia. Products are sold through global healthcare channels and direct distribution networks to audiologists, hospitals, clinics, and individual patients across more than one hundred countries worldwide.
Resumo
Operações
Produtos e/ou serviços de Cochlear
- Auditory Implants: Primary revenue driver consisting of biocompatible internal implants, multi-channel electrode arrays, and external sound processors delivered through global surgical centers and medical networks for individuals diagnosed with severe to profound sensorineural hearing loss.
- Bone Conduction Systems: Acoustic implants and active osseointegrated devices that transmit mechanical sound vibrations directly through skull bones to the functioning inner ear, serving pediatric and adult patients with conductive or mixed hearing impairment.
- Sound Processor Upgrades: Replacement external sound processors, rechargeable power modules, magnet assemblies, and hardware upgrades supplied to established device recipients through direct distribution networks, specialized audiology clinics, online store portals, and localized patient support services.
- Wireless Accessories: Audio streaming hardware, remote microphonic devices, television adapters, and personal phone clips that stream digital audio signals directly into sound processors, enabling improved speech comprehension across complex ambient noise environments.
- Clinical Software and Diagnostics: Programming software suites, audiological diagnostic tools, and digital remote care mobile applications used by audiologists and clinical specialists for device customization, sound fitting, and remote monitoring of implanted patients.
- Surgical Tools and Consumables: Specialized surgical instrumentation, fixation tools, insertion guides, and single-use operational supplies utilized by ENT surgeons during electrode insertion and surgical placement of internal acoustic implant bodies within operating theaters.
equipe executiva do Cochlear
- Diggory William HowittCEO, MD, President & Executive Director
- Sarah ThomChief Financial Officer
- Jan Janssen MSc Elec EngChief Technology Officer
- Karen O'DriscollChief Information Officer
- Kristina DevonVP of Corporate Strategy & Investor Relations
- Rob McGroryGroup General Counsel & Company Secretary
- Jennifer StewartVice President of Communications, Brand & Digital Marketing
- Dean PhizackleaSenior Vice President of Global Strategic Marketing
- Sabina SopovChief People Officer, Global People & Culture
- Greg BodkinSenior Vice President of Global Supply Chain
Últimas notícias sobre a Cochlear
Cochlear faces shareholder class action over guidance downgrade
AustraliaCochlear delivers $2.34B in FY26 sales revenue
AustraliaCochlear secures zero tariff status in US
AustraliaCochlear slashes profit forecast amid global economic headwinds
AustraliaEnvoy Medical reaches pivotal milestone for acclaim Cochlear Implant as debt is slashed
United StatesNexa launch fails to offset Cochlear H1 profit slump
Australia
Comunicados recentes
O que a Cochlear (COH) comunicou ao mercado, do mais recente para o mais antigo.
- Ceasing to be a substantial holder
- Change in substantial holding
Histórico de dividendos
Dividendos por ação pagos pela Cochlear, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2027(até o momento) | A$1.3000 | — | — | A$1.3000 |
| FY2026 | A$2.1500 | A$2.1500 | — | A$4.3000 |
| FY2025 | A$2.1000 | A$2.1500 | — | A$4.2500 |
| FY2024 | A$1.7500 | A$2.0000 | — | A$3.7500 |
| FY2023 | A$1.4500 | A$1.5500 | — | A$4.4500 |
Principais indicadores financeiros
Resultados divulgados pela Cochlear, em AUD.
- Cap. de mercado
- 10,2 bi
- Receita (TTM)
- 2,3 bi
- P/L
- 69.1
- LPA (diluído, TTM)
- 2.3
- Dividend yield
- 2.2%
- Margem de lucro
- 6.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,3 bi | 301 mi | 147,3 mi | |
| 2,3 bi | 406,1 mi | 388,9 mi | |
| 2,2 bi | 521,5 mi | 356,8 mi | |
| 1,9 bi | 389,5 mi | 300,6 mi |